ArticleBreast (Edinburgh, Scotland)2015
Acceptance and adherence to chemoprevention among women at increased risk of breast cancer.
Article in Breast (Edinburgh, Scotland), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Trial
- Participant-Reported Symptoms and Their Effect on Long-Term Adherence in the International Breast Cancer Intervention Study I (IBIS I).Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2017Trial
- Symptoms and QOL as Predictors of Chemoprevention Adherence in NRG Oncology/NSABP Trial P-1.Journal of the National Cancer Institute · 2016Trial
- Adherence to Endocrine Prevention in Patients with Atypical Hyperplasia and Lobular Carcinoma In Situ: Promising Trends from Real-World Use of Low-Dose Tamoxifen.Annals of surgical oncology · 2026Article
- A pilot study of a behavior-change intervention for preventive therapy among women at high risk for invasive breast cancer.BMC medical informatics and decision making · 2026Article
- Pharmacological Prevention in Breast Cancer: Current Evidence, Challenges, and Future Directions.Cancers · 2025Review
- The symptom burden of women with a known risk of breast cancer receiving risk reducing medication.Cancer treatment and research communications · 2025Article
- Subsequent percutaneous breast biopsies after initial atypia diagnosis: The patient burden of long-term follow up.American journal of surgery · 2025Article
- Has the Option of Low-Dose Tamoxifen Impacted Chemoprevention Uptake Among Women with Breast Intra-Epithelial Neoplasia?Annals of surgical oncology · 2024Article
- Risk-management decision-making data from a community-based sample of racially diverse women at high risk of breast cancer: rationale, methods, and sample characteristics of the Daughter Sister Mother Project survey.Breast cancer research : BCR · 2024Article
- Supraclavicular and Contralateral Axillary Lymph Node Involvement in Breast Cancer Patients.Annals of surgical oncology · 2022Article
- Dynamic Changes of Convolutional Neural Network-based Mammographic Breast Cancer Risk Score Among Women Undergoing Chemoprevention Treatment.Clinical breast cancer · 2021Article
- Experiencing the cancer of a loved one influences decision-making for breast cancer prevention.Journal of health psychology · 2020Article
- Benefits and harms of selective oestrogen receptor modulators (SERMs) to reduce breast cancer risk: a cross-sectional study of methods to communicate risk in primary care.The British journal of general practice : the journal of the Royal College of General Practitioners · 2019Article
- Acceptability of Localized Cancer Risk Reduction Interventions Among Individuals at Average or High Risk for Cancer.Cancer prevention research (Philadelphia, Pa.) · 2019Article
- Chemoprevention Uptake among Women with Atypical Hyperplasia and Lobular and Ductal CarcinomaCancer prevention research (Philadelphia, Pa.) · 2017Article
- Clinical Characteristics in Patients with Triple Negative Breast Cancer.International journal of breast cancer · 2017Article
- Article
- Lobular Carcinoma in Situ: A 29-Year Longitudinal Experience Evaluating Clinicopathologic Features and Breast Cancer Risk.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2015Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundChemoprevention is an option for women who are at increased risk of breast cancer (five year risk ≥1.7%). It is uncertain, however, how often women accept and complete five years of therapy and whether clinical or demographic factors predict completion.
methodsMedical records were abstracted for 219 women whose five year risk of breast cancer was ≥1.7% and who were offered chemoprevention while attending a high risk breast clinic at the Moffitt Cancer Center. We examined the likelihood of accepting chemoprevention and completing five years of therapy, and potential clinical and demographic predictors of these outcomes, using multivariable logistic regression and survival analysis models.
resultsThere were 118/219 women (54.4%) who accepted a recommendation for chemoprevention and began therapy. The likelihood of accepting chemoprevention was associated with lifetime breast cancer risk and was higher for women with specific high risk conditions (lobular carcinoma in situ and atypical ductal hyperplasia). Women with osteoporosis and those that consumed alcohol were also more likely to accept medication. There were 58/118 (49.2%) women who stopped medication at least temporarily after starting therapy. Based on survival curves, an estimated 60% of women who begin chemoprevention will complete five years of therapy.
conclusionsA substantial percentage of women at increased risk of breast cancer will decline chemoprevention and among those that accept therapy, approximately 40% will not be able to complete five years of therapy because of side effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.